NAVEEN PEMMARAJU to Animals
This is a "connection" page, showing publications NAVEEN PEMMARAJU has written about Animals.
Connection Strength
0.258
-
Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials. Expert Opin Emerg Drugs. 2020 12; 25(4):491-499.
Score: 0.033
-
Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm. Expert Rev Anticancer Ther. 2020 07; 20(7):543-550.
Score: 0.032
-
Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors. Curr Hematol Malig Rep. 2019 10; 14(5):460-468.
Score: 0.031
-
Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm. Expert Rev Clin Pharmacol. 2019 Oct; 12(10):941-946.
Score: 0.031
-
Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Rev. 2018 03; 32(2):96-105.
Score: 0.027
-
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2014 Jul; 23(7):943-54.
Score: 0.021
-
FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? Cancer. 2011 Aug 01; 117(15):3293-304.
Score: 0.017
-
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. 2024 Mar; 38(3):545-556.
Score: 0.010
-
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood. 2023 09 21; 142(12):1056-1070.
Score: 0.010
-
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126.
Score: 0.010
-
Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun. 2022 04 28; 13(1):2228.
Score: 0.009
-
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol. 2019 Aug; 37(3):240-252.
Score: 0.008
-
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019 01 15; 9(2):4.
Score: 0.007
-
Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017 02; 7(2):156-164.
Score: 0.006
-
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. 2017 03; 31(3):678-687.
Score: 0.006